<DOC>
	<DOCNO>NCT00657878</DOCNO>
	<brief_summary>This study aim test hypothesis artificial prolongation platinum-free interval non-platinum treatment improve effectiveness overall therapy patient ovarian cancer progression occur 6-12 month first-line treatment platinum-derivative .</brief_summary>
	<brief_title>Efficacy Study Chemotherapy Treat Ovarian Cancer Recurrence Prolonging Platinum Free Interval</brief_title>
	<detailed_description>Ovarian cancer deadly gynecologic cancer . Though many patient respond well initially chemotherapy , time suffer relapse . Patients often receive multiple line chemotherapy recurrence , choice chemotherapy depend largely time interval since last therapy . Patients whose disease recur longer 12 month platinum contain treatment consider platinum sensitive , candidate retreatment platinum regimen . Patients disease recurs le 6 month platinum contain treatment consider platinum resistant refractory , treat non platinum chemotherapy . The option treatment less clear patient whose disease recur 6 12 month platinum contain therapy . It hypothesize prolong interval since last platinum treatment use non platinum chemotherapy result well outcomes patient . This study evaluate experimental sequence non platinum base chemotherapy , follow late progression platinum base chemotherapy superior , term effect overall survival , standard inverse sequence treatment .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histological cytological diagnosis ovarian cancer Disease recurrence 6 12 month firstline platinum base therapy Indication chemotherapy , 2 previous line previous therapy Life expectancy 3 month Previous concomitant malignant malignancy ( exclude adequately treat basoor squamocellular carcinoma skin carcinoma situ cervix ) ECOG Performance Status least 3 Previous treatment stealth liposomal doxorubicin Residual peripheral neuropathy Grade 3 high Heart disease ( congestive heart failure , myocardial infarction within 6 month study entry , atrioventricular block grade , severe arrhythmia ) Neutrophils &lt; 2000 x mm3 , platelet &lt; 100000 x mm3 Inadequate renal function ( creatinine great 1.25 x normal value ) liver function ( ALT AST great 1.25 x normal value ) Present suspect hemorrhagic syndrome Inability comply protocol followup Inability access study site clinical visit Refusal inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>platinum free interval</keyword>
	<keyword>chemotherapy</keyword>
</DOC>